Duyuru • May 21
BioSyent Inc. Announces Health Canada Approval of Thyconvi (Levothyroxine Oral Solution) BioSyent Inc. announced that Health Canada has approved Thyconvi (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (TSH) suppression. BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi in Canada. Thyconvi is an oral liquid dosage containing 20 micrograms (mcg) of levothyroxine sodium per millilitre (mL). Thyconvi is indicated for: Hypothyroidism - as a replacement or supplemental therapy in patients of any age with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism of any etiology, in any state (including pregnancy) except transient hypothyroidism during the recovery phase of subacute thyroiditis. Pituitary Thyrotropin (TSH) Suppression - as an adjunct to surgery and radioactive iodine therapy in the management of thyrotropin-dependent well-differentiated papillary or follicular carcinoma of the thyroid. Thyconvi is supplied in a package of two 75 mL bottles without the need for refrigeration. Thyconvi offers broad, convenient dose flexibility for patients who have challenges taking solid doses. Declared Dividend • May 18
First quarter dividend of CA$0.055 announced Shareholders will receive a dividend of CA$0.055. Ex-date: 29th May 2026 Payment date: 15th June 2026 Dividend yield will be 1.5%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (25% earnings payout ratio) and cash flows (21% cash payout ratio). The dividend has increased by an average of 11% per year over the past 3 years and payments have been stable during that time. EPS is expected to grow by 49% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 17
First quarter 2026 earnings released: EPS: CA$0.21 (vs CA$0.21 in 1Q 2025) First quarter 2026 results: EPS: CA$0.21 (up from CA$0.21 in 1Q 2025). Revenue: CA$13.9m (up 27% from 1Q 2025). Net income: CA$2.34m (up 1.1% from 1Q 2025). Profit margin: 17% (down from 21% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 23% per year. Duyuru • May 16
BioSyent Inc. Declares Second Quarter 2026 Dividend, Payable on June 15, 2026 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of CAD 0.055 per common share. Duyuru • May 08
BioSyent Inc. to Report Q1, 2026 Results on May 14, 2026 BioSyent Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026 Reported Earnings • Mar 20
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CA$0.80 (up from CA$0.63 in FY 2024). Revenue: CA$43.1m (up 23% from FY 2024). Net income: CA$9.01m (up 24% from FY 2024). Profit margin: 21% (in line with FY 2024). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 1.3%. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Mar 13
BioSyent Inc. to Report Q4, 2025 Results on Mar 19, 2026 BioSyent Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026 Duyuru • Mar 03
BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million. BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc from a group of shareholders for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow, and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million.
For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million.
Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026.
Rory Cattanach of Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc.
BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million on February 8, 2026. A cash payment of CAD 22.5 million, of which CAD 0.2 million will be satisfied by granting 12,666 Restricted Share Units to certain Oral Science employees, vesting on the second anniversary of the grant date. Also issued 234,192 common shares valued at CAD 3.0 million, of which 167,635 are under a two-year escrow and 66,557 are under a two-year lock-up, releasing 25% every six months. An additional CAD 2 million cash was paid at closing for excess working capital. The sellers may also receive a contingent earn-out in 2027 based on 2025–2026 performance and royalties until 2033 of up to CAD 6 million. Upcoming Dividend • Feb 20
Upcoming dividend of CA$0.055 per share Eligible shareholders must have bought the stock before 27 February 2026. Payment date: 13 March 2026. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Canadian dividend payers (5.5%). Lower than average of industry peers (2.0%). Buy Or Sell Opportunity • Feb 17
Now 22% undervalued Over the last 90 days, the stock has risen 35% to CA$14.50. The fair value is estimated to be CA$18.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 19%. Duyuru • Feb 17
BioSyent Inc., Annual General Meeting, May 14, 2026 BioSyent Inc., Annual General Meeting, May 14, 2026. Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CA$14.51, the stock trades at a forward P/E ratio of 17x. Average trailing P/E is 16x in the Pharmaceuticals industry in Canada. Total returns to shareholders of 106% over the past three years. Duyuru • Feb 09
BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million. BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million.
For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million.
Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026.
Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc. Declared Dividend • Feb 02
Third quarter dividend increased to CA$0.055 Dividend of CA$0.055 is 10.0% higher than last year. Ex-date: 27th February 2026 Payment date: 13th March 2026 Dividend yield will be 1.6%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (32% cash payout ratio). The dividend has increased by an average of 11% per year over the past 3 years and payments have been stable during that time. EPS is expected to grow by 25% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Jan 30
BioSyent Inc. Declares Quarterly Dividend for the First Quarter of 2026, Payable on March 13, 2026 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on March 13, 2026, to shareholders of record at the close of business on February 27, 2026. This first quarter 2026 dividend represents a 10% increase from the fourth quarter 2025 dividend of $0.05 per common share. Declared Dividend • Nov 24
Third quarter dividend of CA$0.05 announced Shareholders will receive a dividend of CA$0.05. Ex-date: 28th November 2025 Payment date: 15th December 2025 Dividend yield will be 1.8%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (31% cash payout ratio). The dividend has increased by an average of 7.7% per year over the past 3 years and payments have been stable during that time. EPS is expected to grow by 27% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Nov 22
BioSyent Declares Fourth Quarter 2025 Dividend, Payable on December 15, 2025 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. This fourth quarter 2025 dividend compares with the third quarter 2025 dividend of $0.05 per common share. Reported Earnings • Nov 21
Third quarter 2025 earnings released: EPS: CA$0.24 (vs CA$0.20 in 3Q 2024) Third quarter 2025 results: EPS: CA$0.24 (up from CA$0.20 in 3Q 2024). Revenue: CA$12.2m (up 28% from 3Q 2024). Net income: CA$2.68m (up 16% from 3Q 2024). Profit margin: 22% (down from 24% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 14% per year. Duyuru • Nov 14
BioSyent Inc. to Report Q3, 2025 Results on Nov 20, 2025 BioSyent Inc. announced that they will report Q3, 2025 results After-Market on Nov 20, 2025 Declared Dividend • Aug 25
Second quarter dividend of CA$0.05 announced Shareholders will receive a dividend of CA$0.05. Ex-date: 29th August 2025 Payment date: 15th September 2025 Dividend yield will be 1.6%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (31% cash payout ratio). The dividend has increased by an average of 12% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 39% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 22
Second quarter 2025 earnings released: EPS: CA$0.18 (vs CA$0.14 in 2Q 2024) Second quarter 2025 results: EPS: CA$0.18 (up from CA$0.14 in 2Q 2024). Revenue: CA$10.2m (up 14% from 2Q 2024). Net income: CA$2.02m (up 28% from 2Q 2024). Profit margin: 20% (up from 18% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 15% per year. Duyuru • Aug 22
BioSyent Inc. Declares Dividend for Third Quarter of 2025, Payable on September 15, 2025 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.05 per common share, payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. This third quarter 2025 dividend compares with the second quarter 2025 dividend of CAD 0.05 per common share. Duyuru • Aug 15
BioSyent Inc. to Report Q2, 2025 Results on Aug 21, 2025 BioSyent Inc. announced that they will report Q2, 2025 results After-Market on Aug 21, 2025 New Risk • Jul 21
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 100% Dividend yield: 1.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Dividend is not well covered by cash flows (100% cash payout ratio). Market cap is less than US$100m (CA$128.9m market cap, or US$94.1m). Price Target Changed • May 20
Price target increased by 18% to CA$13.00 Up from CA$11.00, the current price target is provided by 1 analyst. New target price is 11% above last closing price of CA$11.70. Stock is up 30% over the past year. The company is forecast to post earnings per share of CA$0.75 for next year compared to CA$0.63 last year. Declared Dividend • May 19
First quarter dividend of CA$0.05 announced Shareholders will receive a dividend of CA$0.05. Ex-date: 30th May 2025 Payment date: 13th June 2025 Dividend yield will be 1.6%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (19% earnings payout ratio) and cash flows (57% cash payout ratio). The dividend has increased by an average of 12% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 34% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 17
First quarter 2025 earnings released: EPS: CA$0.21 (vs CA$0.15 in 1Q 2024) First quarter 2025 results: EPS: CA$0.21 (up from CA$0.15 in 1Q 2024). Revenue: CA$11.0m (up 42% from 1Q 2024). Net income: CA$2.32m (up 31% from 1Q 2024). Profit margin: 21% (down from 23% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year. Duyuru • May 16
BioSyent Inc. Declares Second Quarter 2025 Dividend, Payable on June 13, 2025 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on June 13, 2025, to shareholders of record at the close of business on May 30, 2025. This second quarter 2025 dividend compares with the first quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors. Duyuru • May 09
BioSyent Inc. to Report Q1, 2025 Results on May 15, 2025 BioSyent Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025 Recent Insider Transactions Derivative • Apr 07
Chairman exercised options to buy CA$243k worth of stock. On the 31st of March, René Goehrum exercised options to buy 24k shares at a strike price of around CA$3.72, costing a total of CA$89k. Since June 2024, René's direct individual holding has increased from 997.97k shares to 1.04m. Company insiders have collectively bought CA$120k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Mar 14
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CA$0.63 (up from CA$0.54 in FY 2023). Revenue: CA$35.0m (up 11% from FY 2023). Net income: CA$7.27m (up 13% from FY 2023). Profit margin: 21% (in line with FY 2023). Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) also missed analyst estimates by 1.6%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 10% per year and the company’s share price has also increased by 10% per year. Duyuru • Mar 07
BioSyent Inc. to Report Q4, 2024 Results on Mar 13, 2025 BioSyent Inc. announced that they will report Q4, 2024 results After-Market on Mar 13, 2025 Duyuru • Mar 05
BioSyent Inc., Annual General Meeting, May 15, 2025 BioSyent Inc., Annual General Meeting, May 15, 2025. Location: ontario, mississauga Canada Upcoming Dividend • Feb 21
Upcoming dividend of CA$0.05 per share Eligible shareholders must have bought the stock before 28 February 2025. Payment date: 14 March 2025. Payout ratio is a comfortable 29% but the company is paying out more than the cash it is generating. Trailing yield: 1.6%. Lower than top quartile of Canadian dividend payers (6.4%). Lower than average of industry peers (2.4%). Declared Dividend • Feb 03
Third quarter dividend increased to CA$0.05 Dividend of CA$0.05 is 11% higher than last year. Ex-date: 28th February 2025 Payment date: 14th March 2025 Dividend yield will be 1.7%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (29% earnings payout ratio) but not covered by cash flows (108% cash payout ratio). The dividend has increased by an average of 6.1% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 41% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Jan 31
BioSyent Inc. Declares First Quarter 2025 Dividend, Payable on March 14, 2025 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on March 14, 2025, to shareholders of record at the close of business on February 28, 2025. This first quarter 2025 dividend of $0.05 per common share represents an 11.1% increase from the fourth quarter 2024 dividend of $0.045 per common share. Declared Dividend • Nov 22
Third quarter dividend of CA$0.045 announced Shareholders will receive a dividend of CA$0.045. Ex-date: 29th November 2024 Payment date: 16th December 2024 Dividend yield will be 1.6%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but not covered by cash flows (107% cash payout ratio). The dividend has increased by an average of 6.1% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 41% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Nov 21
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: CA$0.20 (in line with 3Q 2023). Revenue: CA$9.56m (up 7.7% from 3Q 2023). Net income: CA$2.31m (down 1.8% from 3Q 2023). Profit margin: 24% (down from 27% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.2%. Earnings per share (EPS) also surpassed analyst estimates by 43%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 10% per year and the company’s share price has also increased by 10% per year. Duyuru • Nov 20
December 16, 2024 Declares Fourth Quarter 2024 Dividend, Payable on December 16, 2024 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. This fourth quarter 2024 dividend compares with the third quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors. Duyuru • Nov 14
BioSyent Inc. to Report Q3, 2024 Results on Nov 20, 2024 BioSyent Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 20, 2024 Declared Dividend • Aug 29
Second quarter dividend of CA$0.045 announced Shareholders will receive a dividend of CA$0.045. Ex-date: 4th September 2024 Payment date: 15th September 2024 Dividend yield will be 1.6%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (13% earnings payout ratio) and cash flows (30% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 36% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 27
Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat Second quarter 2024 results: EPS: CA$0.14 (up from CA$0.12 in 2Q 2023). Revenue: CA$8.94m (up 12% from 2Q 2023). Net income: CA$1.58m (up 6.5% from 2Q 2023). Profit margin: 18% (in line with 2Q 2023). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 12% per year and the company’s share price has also increased by 12% per year. Duyuru • Aug 27
Biosyent Inc Declares Dividend for the Third Quarter of 2024, Payable on September 15, 2024 BioSyent Inc. announced that its Board of Directors have declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on September 15, 2024, to shareholders of record at the close of business on September 4, 2024. This third quarter 2024 dividend compares with the second quarter 2024 dividend of $0.045 per common share. Recent Insider Transactions • Jun 23
Insider recently sold CA$55k worth of stock On the 20th of June, Sharan Raghubir sold around 6k shares on-market at roughly CA$10.01 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$79k more than they bought in the last 12 months. Declared Dividend • May 20
First quarter dividend of CA$0.045 announced Shareholders will receive a dividend of CA$0.045. Ex-date: 31st May 2024 Payment date: 15th June 2024 Dividend yield will be 1.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (27% earnings payout ratio) and cash flows (30% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 15% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 19
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2024 results: EPS: CA$0.15 (up from CA$0.097 in 1Q 2023). Revenue: CA$7.73m (up 19% from 1Q 2023). Net income: CA$1.77m (up 51% from 1Q 2023). Profit margin: 23% (up from 18% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates by 87%. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Duyuru • May 18
BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024. This second quarter 2024 dividend compares with the first quarter 2024 dividend of $0.045 per common share. Duyuru • May 11
BioSyent Inc. to Report Q1, 2024 Results on May 16, 2024 BioSyent Inc. announced that they will report Q1, 2024 results at 4:00 PM, US Eastern Standard Time on May 16, 2024 Duyuru • Mar 19
BioSyent Inc., Annual General Meeting, May 16, 2024 BioSyent Inc., Annual General Meeting, May 16, 2024. Reported Earnings • Mar 14
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CA$0.54 (up from CA$0.44 in FY 2022). Revenue: CA$31.6m (up 13% from FY 2022). Net income: CA$6.46m (up 18% from FY 2022). Profit margin: 20% (in line with FY 2022). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 8.6%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Duyuru • Mar 07
BioSyent Inc. to Report Q4, 2023 Results on Mar 13, 2024 BioSyent Inc. announced that they will report Q4, 2023 results After-Market on Mar 13, 2024 Upcoming Dividend • Feb 21
Upcoming dividend of CA$0.045 per share Eligible shareholders must have bought the stock before 28 February 2024. Payment date: 15 March 2024. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Canadian dividend payers (6.4%). In line with average of industry peers (2.3%). Declared Dividend • Feb 08
Third quarter dividend increased to CA$0.045 Dividend of CA$0.045 is 13% higher than last year. Ex-date: 28th February 2024 Payment date: 15th March 2024 Dividend yield will be 1.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (30% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 9.3% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Feb 07
BioSyent Inc. Declares First Quarter 2024 Dividend, Payable on March 15, 2024 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. This first quarter 2024 dividend of $0.045 per common share represents a 12.5% increase from the fourth quarter 2023 dividend of $0.040 per common share. Upcoming Dividend • Nov 22
Upcoming dividend of CA$0.04 per share at 1.9% yield Eligible shareholders must have bought the stock before 29 November 2023. Payment date: 15 December 2023. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Canadian dividend payers (6.7%). Lower than average of industry peers (2.5%). Price Target Changed • Nov 18
Price target increased by 13% to CA$9.00 Up from CA$8.00, the current price target is provided by 1 analyst. New target price is 9.8% above last closing price of CA$8.20. Stock is up 12% over the past year. The company is forecast to post earnings per share of CA$0.58 for next year compared to CA$0.44 last year. Reported Earnings • Nov 17
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: EPS: CA$0.20 (up from CA$0.12 in 3Q 2022). Revenue: CA$8.87m (up 31% from 3Q 2022). Net income: CA$2.35m (up 62% from 3Q 2022). Profit margin: 27% (up from 21% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) also surpassed analyst estimates by 100%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 17
BioSyent Inc. Declares Fourth Quarter 2023 Dividend, Payable on December 15, 2023 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. This fourth quarter 2023 dividend compares with the third quarter 2023 dividend of $0.04 per common share. Duyuru • Nov 10
BioSyent Inc. to Report Q3, 2023 Results on Nov 16, 2023 BioSyent Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 16, 2023 Reported Earnings • Aug 24
Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat Second quarter 2023 results: EPS: CA$0.12 (up from CA$0.098 in 2Q 2022). Revenue: CA$7.96m (up 20% from 2Q 2022). Net income: CA$1.48m (up 22% from 2Q 2022). Profit margin: 19% (in line with 2Q 2022). Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Duyuru • Aug 23
BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on September 15, 2023, to shareholders of record at the close of business on August 31, 2023. This third quarter 2023 dividend compares with the second quarter 2023 dividend of $0.04 per common share. Duyuru • Aug 16
BioSyent Inc. to Report Q2, 2023 Results on Aug 22, 2023 BioSyent Inc. announced that they will report Q2, 2023 results After-Market on Aug 22, 2023 Reported Earnings • May 28
First quarter 2023 earnings: EPS and revenues miss analyst expectations First quarter 2023 results: EPS: CA$0.097 (down from CA$0.13 in 1Q 2022). Revenue: CA$6.48m (down 7.9% from 1Q 2022). Net income: CA$1.18m (down 26% from 1Q 2022). Profit margin: 18% (down from 23% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 16% per year. Duyuru • May 26
BioSyent Inc. Declares Second Quarter 2023 Dividend, Payable on June 15, 2023 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023. This second quarter 2023 dividend compares with the first quarter 2023 dividend of $0.04 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors. Duyuru • May 19
BioSyent Inc. to Report Q1, 2023 Results on May 26, 2023 BioSyent Inc. announced that they will report Q1, 2023 results at 8:00 AM, US Eastern Standard Time on May 26, 2023 Reported Earnings • Mar 22
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: CA$0.44 (down from CA$0.49 in FY 2021). Revenue: CA$27.9m (down 2.4% from FY 2021). Net income: CA$5.46m (down 13% from FY 2021). Profit margin: 20% (down from 22% in FY 2021). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 1.2%. Revenue is forecast to grow 7.0% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Feb 20
Inaugural dividend of CA$0.04 per share Eligible shareholders must have bought the stock before 27 February 2023. Payment date: 15 March 2023. This is the first dividend for BioSyent since going public. The average dividend yield among industry peers is 2.6%. Duyuru • Feb 02
BioSyent Inc. Declares Dividend for the First Quarter 2023, Payable on March 15, 2023 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable on March 15, 2023, to shareholders of record at the close of business on February 28, 2023. This first quarter 2023 dividend compares with the fourth quarter 2022 dividend of $0.04 per common share. Reported Earnings • Nov 18
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: EPS: CA$0.12 (down from CA$0.14 in 3Q 2021). Revenue: CA$6.79m (up 1.5% from 3Q 2021). Net income: CA$1.45m (down 16% from 3Q 2021). Profit margin: 21% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 7.7%. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Price Target Changed • Nov 17
Price target increased to CA$10.00 Up from CA$8.00, the current price target is provided by 1 analyst. New target price is 41% above last closing price of CA$7.08. Stock is down 1.5% over the past year. The company is forecast to post earnings per share of CA$0.47 for next year compared to CA$0.50 last year. Board Change • Nov 17
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Joseph Arcuri was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Nov 11
BioSyent Inc. to Report Q3, 2022 Results on Nov 16, 2022 BioSyent Inc. announced that they will report Q3, 2022 results After-Market on Nov 16, 2022 Buying Opportunity • Nov 04
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 5.8%. The fair value is estimated to be CA$9.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 16%. Duyuru • Oct 13
BioSyent Inc. Declares Quarterly Dividend, Payable on December 15, 2022 BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2022, to shareholders of record at the close of business on November 30, 2022. Reported Earnings • Aug 24
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Second quarter 2022 results: EPS: CA$0.098 (up from CA$0.08 in 2Q 2021). Revenue: CA$6.63m (down 9.0% from 2Q 2021). Net income: CA$1.22m (up 20% from 2Q 2021). Profit margin: 18% (up from 14% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 29%. Over the next year, revenue is forecast to grow 13%, compared to a 24% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Duyuru • Aug 24
BioSyent Inc. Announces Adoption of Dividend Policy BioSyent Inc. announced that its Board of Directors adopted a Dividend Policy in order to establish terms of reference for the Board in its decision-making around the declaration of any dividends to be issued to shareholders of the Company. Duyuru • Aug 17
BioSyent Inc. to Report Q2, 2022 Results on Aug 23, 2022 BioSyent Inc. announced that they will report Q2, 2022 results After-Market on Aug 23, 2022 Duyuru • May 12
BioSyent Inc. to Report Q1, 2022 Results on May 18, 2022 BioSyent Inc. announced that they will report Q1, 2022 results at 8:00 AM, US Eastern Standard Time on May 18, 2022 Price Target Changed • Apr 27
Price target increased to CA$10.00 Up from CA$8.00, the current price target is provided by 1 analyst. New target price is 9.8% above last closing price of CA$9.11. Stock is up 22% over the past year. The company is forecast to post earnings per share of CA$0.54 for next year compared to CA$0.50 last year. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Joseph Arcuri was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 11
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CA$0.49 (up from CA$0.29 in FY 2020). Revenue: CA$28.6m (up 28% from FY 2020). Net income: CA$6.28m (up 66% from FY 2020). Profit margin: 22% (up from 17% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 11%, compared to a 74% growth forecast for the pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has remained flat. Duyuru • Mar 06
BioSyent Inc. to Report Q4, 2021 Results on Mar 09, 2022 BioSyent Inc. announced that they will report Q4, 2021 results After-Market on Mar 09, 2022 Valuation Update With 7 Day Price Move • Nov 25
Investor sentiment improved over the past week After last week's 19% share price gain to CA$8.58, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 24x in the Pharmaceuticals industry in Canada. Total returns to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CA$13.58 per share. Reported Earnings • Nov 20
Third quarter 2021 earnings released: EPS CA$0.14 (vs CA$0.075 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CA$6.69m (up 16% from 3Q 2020). Net income: CA$1.72m (up 80% from 3Q 2020). Profit margin: 26% (up from 17% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CA$0.08 (vs CA$0.056 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CA$7.29m (up 53% from 2Q 2020). Net income: CA$1.02m (up 41% from 2Q 2020). Profit margin: 14% (down from 15% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 7% per year and the company’s share price has also fallen by 7% per year. Valuation Update With 7 Day Price Move • Jun 24
Investor sentiment improved over the past week After last week's 19% share price gain to CA$9.20, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 25x in the Pharmaceuticals industry in Canada. Total loss to shareholders of 4.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CA$11.93 per share. 
